Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post-transplant cyclophosphamide.
Fiche publication
Date publication
septembre 2021
Journal
Cancer medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BERCEANU Ana, Dr DAGUINDAU Etienne
Tous les auteurs :
Jullien M, Orvain C, Berceanu A, Couturier MA, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Klemencie M, Schmidt A, Hunault M, Daguindau E, Roussel X, Delepine P, Guillerm G, Giltat A, François S, Thepot S, Le Gouill S, Béné MC, Chevallier P
Lien Pubmed
Résumé
Three different scoring systems have been developed to assess pre-transplant comorbidity in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): the Hematopoietic Cell Transplantation-Specific Comorbidity Index, the Comorbidity/Age index, and the Augmented Comorbidity/Age index. All were devised to predict overall survival (OS) and disease-free survival (DFS) survivals and non-relapse mortality (NRM) in patients receiving HLA-matched Allo-HSCT, but their performance has scarcely been studied in the haploidentical Allo-HSCT setting with post-transplant cyclophosphamide, a procedure in constant expansion worldwide.
Mots clés
HSCT-CI, PTCY, allogeneic hematopoietic stem cell transplantation, augmented comorbidity/age index, comorbidity/age index, haploidentical
Référence
Cancer Med. 2021 Sep 21;: